Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Olpasiran · AMG-890

Oligonucleotide (siRNA) · developed by AMGEN

Phase 3 Most advanced trial
AMGN Developer
1 Registered trials

What is Olpasiran?

Olpasiran (AMG 890) is an agent given by subcutaneous injection every 12 weeks. It is studied in atherosclerotic cardiovascular disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AMG-890
Drug type
Oligonucleotide (siRNA)
Therapy area
Cardiovascular
Developer
AMGEN (AMGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
8M4GC1EOB4

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05581303 Phase 3 Atherosclerotic Cardiovascular Disease Active not recruiting AMGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Atherosclerotic Cardiovascular Disease

More from AMGEN

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the AMGN page.

Follow AMGN, the company behind Olpasiran

See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.